<?xml version="1.0" encoding="UTF-8"?>
<p>The treatment of dengue, chikungunya, and Zika relies on supportive treatment and symptom relief since there is no antiviral treatment available. Considering the possible complications of these viral diseases, prevention, prompt diagnosis and adequate intervention at the onset of disease symptoms are the main options for reducing the burden of disease. To date, no vaccines are available for Zika, and chikungunya [
 <xref rid="pntd.0008136.ref003" ref-type="bibr">3</xref>, 
 <xref rid="pntd.0008136.ref018" ref-type="bibr">18</xref>]. There is a licensed dengue vaccine available. However, it is not suitable for large-scale use [
 <xref rid="pntd.0008136.ref019" ref-type="bibr">19</xref>]. Thus, the prevention or reduction of the transmission of the mentioned VBDs hinges primarily on control of the mosquito vectors 
 <italic>(e</italic>.
 <italic>g</italic>. 
 <italic>environmental management</italic>, 
 <italic>biological and chemical control)</italic> and interruption of human-vector contact 
 <italic>(e</italic>.
 <italic>g</italic>. 
 <italic>individual protection including the use of repellents</italic>, 
 <italic>clothing that minimises skin exposure</italic>, 
 <italic>and household protection including window and door screens</italic>, 
 <italic>and air-conditioning)</italic>[
 <xref rid="pntd.0008136.ref013" ref-type="bibr">13</xref>, 
 <xref rid="pntd.0008136.ref020" ref-type="bibr">20</xref>].
</p>
